Results of Operations and Financial Condition. On October 29, 2026, Stablecoin Development Corporation (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being “furnished” and shall not be deemed “filed” by the Company for purposes of Section 18 of the Securi…

Results of Operations and Financial Condition. Selected Preliminary Quarter-End Information and Digital Asset Holdings Stablecoin Development Corporation (the “Company”) is providing the following update regarding its digital asset holdings and selected balance sheet information as of September 30, 2026. All figures are preliminary and unaudited, remain subject to the completion of the Company’s quarter-end closing procedures, and are qualified in their entirety by the financial statements to…

Material Modification to Rights of Security Holders. To the extent required by

Director — David Garcia Rios: The filing discloses the appointment of a new Class II director nominated by an investor (SFF) in connection with a securities purchase agreement, which is a board addition rather than an executive departure.

Results of Operations and Financial Condition. On July 31, 2026, the Company issued a press release announcing its results of operations for the quarter ended June 30, 2026 as well as its updated SKY holdings and accumulated staking rewards. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being “furnished” and shall not be deemed “filed” by the Company for purposes of…

Chief Operating Officer — Henry Blynn: Henry Blynn was promoted to Chief Operating Officer from Head of Business Operations and Strategy.

Entry into a Material Definitive Agreement Amendment to October 2025 Pre-Funded Warrants On June 12, 2026, Stablecoin Development Corporation (the “Company”) agreed with R01 Fund LP (“R01”), and on June 15, 2026, the Company agreed with Framework Ventures IV L.P. (“Framework”), in each case, to amend the pre-funded warrants originally issued on October 16, 2025 (the “October 2025 Pre-Funded Warrants”) in order to remove certain restrictions on exercisability. Following the amendment of the Oc…

Material Modification to Rights of Security Holders The information contained in

Results of Operations and Financial Condition. On May 20, 2026, the Company issued a press release announcing its results of operations for the quarter ended March 31, 2026 as well as its updated SKY holdings and accumulated staking rewards. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being “furnished” and shall not be deemed “filed” by the Company for purposes of…

Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review. On April 27, 2026, the audit committee of the board of directors and management of the Company concluded that the Company’s previously issued audited consolidated financial statements for the year ended December 31, 2025, should no longer be relied upon because of an error in the Company’s accounting relating to certain outstanding pre-funded warrants issued on October 16, 2025 (the “…

Results of Operations and Financial Condition. On April 6, 2026, Stablecoin Development Corporation (the “Company”) issued a press release announcing its updated SKY holdings and accumulated staking rewards. As discussed in the press release, the Company engages in SKY-related on-chain activities, including staking, and the Company holds approximately 2.15 billion SKY tokens as of March 31, 2026. The text of the press release is included as Exhibit 99.1 to this Form 8-K. The information discl…

The filing describes the approval and details of a new equity incentive plan, which is not directly related to management changes.

Results of Operations and Financial Condition. On March 23, 2026, the Company issued a press release announcing its updated SKY holdings and accumulated staking rewards. As discussed in the press release, the Company engages in SKY-related on-chain activities, including staking, and the Company holds approximately 2.06 billion SKY tokens as of March 16, 2026. The text of the press release is included as Exhibit 99.1 to this Form 8-K. The information disclosed under this Item 2.02, including E…

Material Modification to Rights of Security Holders To the extent required by

Other Events. NovaBay Pharmaceuticals, Inc. (the “ Company ”) will hold a special meeting of stockholders of the Company on March 12, 2026 at 11:00 a.m. Eastern Time (the “ Special Meeting ”), at which stockholders will be asked to vote on, among other corporate actions, proposals approving the issuance of the Company’s common stock upon the exercise of the pre-funded warrants that were issued in our private placement transactions on each of January 16, 2026 and October 16, 2025. Forward-Look…

Changes in Registrant ’ s Certifying Accountant. On January 30, 2026, with the approval of the Audit Committee, CBIZ CPAs, P.C. (“CBIZ”) was engaged as the Company’s new independent registered public accounting firm for the fiscal year ending December 31, 2025. During the fiscal years ended December 31, 2025 and 2024 and the subsequent interim period through January 30, 2026, neither the Company nor anyone on its behalf consulted with CBIZ regarding: (i) the application of accounting principl…

Changes in Registrant ’ s Certifying Accountant. (a) Independent Registered Public Accounting Firm Declining to Stand for Re-appointment On January 22, 2026, WithumSmith+Brown, PC (“Withum”) notified NovaBay Pharmaceuticals, Inc. (the “Company”) that they were declining to stand for re-appointment as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. Withum had served as the Company’s independent registered public accounting firm since 20…

Entry Into a Material Definitive Agreement. On January 20, 2026, NovaBay Pharmaceuticals, Inc. (the “Company”) entered into an ATM Sales Agreement (the “Sales Agreement”) with Virtu Americas LLC (“Virtu”), pursuant to which the Company may offer and sell shares of its common stock, par value $0.01 per share (“Common Stock”), having an aggregate offering price of up to $100.0 million from time to time through or to Virtu as its sales agent or principal. Sales of Common Stock through Virtu, if…

Entry Into a Material Definitive Agreement. Securities Purchase Agreement and Pre-Funded Warrants On January 16, 2026, NovaBay Pharmaceuticals, Inc. (the “Company”), entered into a Securities Purchase Agreement (the “SPA”) with each of R01 Fund LP, Framework Ventures IV L.P., Tether Investments, S.A. de C.V. and Sky Frontier Foundation (together, the “Purchasers”). Pursuant to the SPA, the Company issued and sold pre-funded warrants (the “Pre-Funded Warrants”) to purchase an aggregate of 837,…

Unregistered Sale of Equity Securities. The information disclosed in

Entry Into a Material Definitive Agreement. The information disclosed in

Changes in Control of Registrant. As a result of the transactions described in

Material Modification to Rights of Security Holders. At the Annual Meeting of Stockholders held on October 16, 2025, the stockholders of the Company approved a proposal granting the board of directors of the Company (the “Board”) full authority to effect a reverse stock split (the “Reverse Stock Split”) of all outstanding (or held in treasury) shares of Common Stock at a ratio of not less than 1-for-2 and not more than 1-for-10, with the exact ratio to be determined by the Board within such r…

Chief Executive Officer, Director — David Elliot Lazar: David Elliot Lazar resigned as CEO and director, and Michael Kazley was appointed as the new CEO and Chairman.

Unregistered Sale of Equity Securities. On October 9, 2025, David Elliot Lazar (“Lazar”), the former Chief Executive Officer and director of NovaBay Pharmaceuticals, Inc. (the “Company”), entered into a Securities Purchase Agreement (the “SPA”) with R01 Fund LP and Framework Ventures IV L.P. (“Framework,” and together with R01, the “Purchasers”). Pursuant to the SPA, Mr. Lazar received an aggregate purchase price of $9,850,000 to (i) sell to the Purchasers an aggregate of 441,325 shares of th…